Accueil   Diary - News   All news A major step in the restoration of Gut Microbiota: MaaT Pharma and Biocodex to industrialize FMT & develop an oral formulation

A major step in the restoration of Gut Microbiota: MaaT Pharma and Biocodex to industrialize FMT & develop an oral formulation


 

Lyon (France), June 8, 2017. Following their investment in MaaT Pharma a year ago, Biocodex is taking a further step with the French microbiotech1 company, marking a turning point in the history of the European microbiota specialist.

 

MaaT Pharma’s disruptive business model: exponential growth

 

Within 2 years, the microbiotech company has become a leader in the field of Gut Microbiota, offering a selective approach by leveraging intestinal homeostasis to improve the recovery and treatment of patients with life-threatening conditions. MaaT Pharma launched the 1st European GMP2 -compliant FMT facility, followed immediately by the launch of its first clinical trial in June 2016 making it one of the most advanced microbiota companies. The microbiotech is currently conducting three clinical trials in onco-hematology and infectious diseases. In a fast-growing industry, the Company is now partnering with Biocodex for the industrialization of FMT, and in particular the development of an oral formulation. MaaT Pharma aims to receive marketing authorization for 2023.

 

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree